obinutuzumab   

GtoPdb Ligand ID: 6941

Synonyms: GA-101 | GA101 | Gazyva®
obinutuzumab is an approved drug (FDA (2013), EMA (2014))
Compound class: Antibody
Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: obinutuzumab

References
1. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al.. (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Blood, 117 (17): 4519-29. [PMID:21378274]
2. Genentech Media. 
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis.
Accessed on 25/09/2019. Modified on 25/09/2019. Genentech, https://www.gene.com/media/press-releases/14811/2019-09-17/fda-grants-breakthrough-therapy-designat?elqTrackId=8dd752c5464246d2864338e62ba78820&elq=7aed654c4c2d4934a203067e44937351&elqaid=26161&elqat=1&elqCampaignId=10601
3. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013)
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Mol. Cancer Ther., 12 (10): 2031-42. [PMID:23873847]
4. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. (2014)
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab.
Leuk. Lymphoma, 55 (1): 188-90. [PMID:23537278]